Bionsight is a drug discovery company that integrates the power of chemoproteomics and AI technologies to facilitate target identification and off-target profiling within the drug development process. We offer a chemoproteomics platform named Javelin, capable of identifying thousands of proteins, thereby enabling comprehensive protein-ligand interaction mapping on a proteome-wide scale. This state-of-the-art method provides numerous benefits for drug discovery. It empowers us to uncover multiple interactions, provides broad scope applicability to diverse targets, opens the potential to delve into the mechanisms of action and side effects, and presents a cutting-edge strategy to address previously "undruggable" targets.
